RankingsPricing
  1. US-listed companies
  2. Aldeyra Therapeutics, Inc.
  3. Raw

Aldeyra Therapeutics, Inc.ALDX

Market cap
$300.08M
P/E ratio
SummaryFinancials
Back to summarized table
Dec 31,
2014		Dec 31,
2015		Dec 31,
2016		Dec 31,
2017		Dec 31,
2018		Dec 31,
2019		Dec 31,
2020		Dec 31,
2021		Dec 31,
2022		Dec 31,
2023		Dec 31,
2024
Net loss------60,826,831-37,553,729-57,776,274-62,024,636-37,542,510-55,851,444
Stock-based compensation22334877868
Non-cash interest expense150,85235,82927,31420,34159,322248,567566,020409,471331,150354,193177,326
Net amortization of premium on marketable securities---266,106-129,245237,541583,70191,231-47,24514,5422
Depreciation1,06918,77835,79237,84971,00396,30556,221264,180258,707262,780249,623
Prepaid expenses and other current assets224,156264,984-278,870800,285150,627454,4293-2,239,1764-1,734,912-2,066,111
Accounts payable-559509,866-575,719725,5222-2,846,142-426,664638,064-886,0771-1,157,604
Accrued expenses and other liabilities776,613291,943759,822290,21436-5,006,37551-8,078,1645
Deferred collaboration revenue---------6-
Net cash used in operating activities-----29,857,131-44,984,226-37,493,455-42,555,907-56,637,187-30,326,128-43,208,747
Acquisitions of fixed assets14,06286,11911,81024,759262,9669,529-7,80616,317--
Purchases of marketable securities--------93-97
Maturities of marketable securities--1625377635-633052
Net cash (used in) provided by investing activities-----23,335,5761829-7,806-29,954,53030-44,915,755
Issuance costs----------267,261
Proceeds from Stock Options Exercised-----1151194,129350,279
Tax withholding payments for net share-settled equity awards---------532,951-
Proceeds from employee stock purchase plan-----194,849126,96661,52996,665111,10238,060
Debt end of term charge paid in cash-----123,186---1292,500
Net cash used in financing activities----8124421941-1,270,220-171,422
NET DECREASE IN CASH AND CASH EQUIVALENTS------2,931,64233152-85,371,625-1,596,348-88,295,924
Cash paid during the period for interest----88,963238,49111122